Data from Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer

• DOI: 10.1158/1078-0432.c.6528828.v1
• Publication Date: 2023-04-01T06:21:53Z
• Authors: Siwen Hu-Lieskovan; Aaron Lisberg; Jesse M. Zaretsky; Tristan R. Grogan; Hira Rizvi; Daniel K. Wells; James Carroll; Amy Cummings; John Madrigal; Benjamin Jones; Jacklin Gukasyan; I. Peter Shintaku; Dennis Slamon; Steven Dubinett; Jonathan W. Goldman; David Elashoff; Matthew D. Hellmann; Antoni Ribas; Edward B. Garon
• Keywords: Tumor-infiltrating lymphocytes; Progression-free survival

<div>AbstractPurpose:<p>Several biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC), CD8 cells melanoma. We sought examine the relationship between these distinct variables blockade long-term benefit.</p>Experimental Design:<p>We assessed association baseline characteristics (TMB, PD-L1, CD4, CD8) clinical features outcome 38 patients advanced NSCLC treated pembrolizumab (median follow-up of 4.5 years, range 3.8–5.5 years).</p>Results:<p>PD-L1 expression infiltration correlated each other significantly objective rate (ORR) progression-free survival (PFS). TMB was independent expression, trended towards ORR PFS. There no CD4 outcomes. Only overall (OS). Among 5 >3 years additional systemic therapy, only discriminating feature. The increased predictive value for PFS OS composite biomarker inclusive CD8, limited.</p>Conclusions:<p>In follow up, TMB, were benefit from blockade. Pretreatment T lymphocyte OS, whereas models incorporating infiltrating lymphocytes did not substantially add alone OS.</p></div>